{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:11:57Z","timestamp":1789506717599,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011011","name":"Junta de Andaluc\u00eda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006393","name":"Universidad de Granada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006393","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.vaccine.2026.128790","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T21:06:17Z","timestamp":1780607177000},"page":"128790","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Young adults at risk of emerging serotype 4 invasive pneumococcal disease vs. other serotypes in Andalusia (Spain), 2022 to 2024: optimising conjugated vaccines strategies"],"prefix":"10.1016","volume":"88","author":[{"given":"Elvira","family":"Mar\u00edn-Caba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Lorusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Sempere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Juan","family":"Jim\u00e9nez-Mole\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Rivera-Izquierdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10100","key":"10.1016\/j.vaccine.2026.128790_bb0005","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0140-6736(17)32152-9","article-title":"Global, regional, and national age-sex specific mortality for 264 causes of death, 1980\u20132016: a systematic analysis for the global burden of disease study 2016","volume":"390","author":"Naghavi","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128790_bb0010","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.3390\/microorganisms11061376","article-title":"Pneumococcal serotype evolution and burden in European adults in the last decade: a systematic review","volume":"11","author":"Teixeira","year":"2023","journal-title":"Microorganisms"},{"key":"10.1016\/j.vaccine.2026.128790_bb0015","series-title":"Disease information about pneumococcal disease. Facts [internet]","author":"European Centre for Disease Prevention and Control","year":"2023"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128790_bb0020","first-page":"74","article-title":"Invasive pneumococcal disease in Spain in 2023","volume":"32","author":"Soler-Soneira","year":"2024","journal-title":"Weekly Epidemiol. Bull."},{"issue":"10","key":"10.1016\/j.vaccine.2026.128790_bb0025","doi-asserted-by":"crossref","first-page":"e744","DOI":"10.1016\/S2666-5247(22)00127-6","article-title":"Effect of pneumococcal conjugate vaccines and SARS-CoV-2 on antimicrobial resistance and the emergence of Streptococcus pneumoniae serotypes with reduced susceptibility in Spain, 2004-20: a national surveillance study","volume":"3","author":"Sempere","year":"2022","journal-title":"Lancet Microbe"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128790_bb0030","doi-asserted-by":"crossref","first-page":"e3778","DOI":"10.1093\/cid\/ciaa1483","article-title":"Nationwide trends of invasive pneumococcal disease in Spain from 2009 through 2019 in children and adults during the pneumococcal conjugate vaccine era","volume":"73","author":"de Miguel","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"45","key":"10.1016\/j.vaccine.2026.128790_bb0035","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2024.29.45.2400108","article-title":"Non-invasive Streptococcus pneumoniae infections are associated with different serotypes than invasive infections, Belgium, 2020 to 2023","volume":"29","author":"Passaris","year":"2024","journal-title":"Euro Surveill"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128790_bb0040","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1128\/JCM.01937-09","article-title":"Association of serotypes of Streptococcus pneumoniae with age in invasive pneumococcal disease","volume":"48","author":"Im\u00f6hl","year":"2010","journal-title":"J Clin Microbiol"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128790_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms9112245","article-title":"Serotypes in adult pneumococcal pneumonia in Spain in the era of conjugate vaccines","volume":"9","author":"Fern\u00e1ndez-Delgado","year":"2021","journal-title":"Microorganisms"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128790_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2024.106204","article-title":"Surveillance of invasive pneumococcal disease in Spain exploring the impact of the COVID-19 pandemic (2019-2023)","volume":"89","author":"P\u00e9rez-Garc\u00eda","year":"2024","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2026.128790_bb0055","series-title":"Annual query 6675","author":"Institute of Statistics and Cartography of Andalusia","year":"2025"},{"key":"10.1016\/j.vaccine.2026.128790_bb0060","author":"Ministry of Health"},{"key":"10.1016\/j.vaccine.2026.128790_bb0065","unstructured":"ANDAVAC. Regional Office of Health, Presidency and Emergencias, Government of Andalusia. Pneumococcal vaccination uptake in Andalusia (birth cohorts 2023-2024). https:\/\/www.andavac.es\/wp-content\/uploads\/infografias\/cobertura-vacunal-neumococo-lactantes-andalucia.pdf."},{"key":"10.1016\/j.vaccine.2026.128790_bb0070","unstructured":"ANDAVAC. Regional Office of Health, Presidency and Emergencies, Government of Andalusia. Pneumococcal vaccination in risk groups. https:\/\/www.andavac.es\/vacunacion-en-grupos-de-riesgo\/neumococo\/."},{"key":"10.1016\/j.vaccine.2026.128790_bb0075","unstructured":"ANDAVAC. Regional Office of Health, Presidency and Emergencies, Government of Andalusia. PCV13 and PCV20 uptake in population aged 60\u201380 years, Andalusia. https:\/\/www.andavac.es\/wp-content\/uploads\/infografias\/cobertura-vacunacion-neumococo-13-valente.pdf."},{"issue":"7","key":"10.1016\/j.vaccine.2026.128790_bb0080","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.3201\/eid2707.204403","article-title":"Whole-genome analysis of Streptococcus pneumoniae serotype 4 causing outbreak of invasive pneumococcal disease, Alberta, Canada","volume":"27","author":"Kellner","year":"2021","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128790_bb0085","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/cid\/ciad597","article-title":"Invasive pneumococcal disease and potential impact of pneumococcal conjugate vaccines among adults, including persons experiencing homelessness\u2014Alaska, 2011-2020","volume":"78","author":"Steinberg","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128790_bb0090","article-title":"Increased proportions of invasive pneumococcal disease cases among adults experiencing homelessness sets stage for new serotype 4 capsular-switch recombinant","author":"Beall","year":"2024","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128790_bb0095","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.amjms.2024.02.002","article-title":"Neighborhood-level disadvantages increase risk for invasive pneumococcal disease","volume":"367","author":"Minassian","year":"2024","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.vaccine.2026.128790_bb0100","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ijid.2013.12.013","article-title":"Smoking and alcohol abuse are the most preventable risk factors for invasive pneumonia and other pneumococcal infections","volume":"25","author":"Grau","year":"2014","journal-title":"Int J Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128790_bb0105","doi-asserted-by":"crossref","first-page":"e948","DOI":"10.1093\/cid\/ciaa1680","article-title":"Invasive pneumococcal strain distributions and isolate clusters associated with persons experiencing homelessness during 2018","volume":"72","author":"Metcalf","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128790_bb0110","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.vaccine.2021.10.046","article-title":"International links between Streptococcus pneumoniae vaccine serotype 4 sequence type (ST) 801 in Northern European shipyard outbreaks of invasive pneumococcal disease","volume":"40","author":"Gladstone","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128790_bb0115","author":"World Health Organization"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128790_bb0120","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1080\/21645515.2016.1210744","article-title":"Pneumococcal vaccination coverages among low-, intermediate-, and high-risk adults in Catalonia","volume":"12","author":"Vila-Corcoles","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2026.128790_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127364","article-title":"Evaluation of vaccine uptake and opportunity of in-hospital vaccination against pneumococcus in vulnerable hospitalized patients","volume":"61","author":"Mar\u00edn-Caba","year":"2025","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128790_bb0130","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.vaccine.2026.128790_bb0135","series-title":"Decree 228\/2015, of December 15, which establishes the legal regime of the public health system of Andalusia","volume":"228","author":"Junta de Andaluc\u00eda","year":"2015"},{"key":"10.1016\/j.vaccine.2026.128790_bb0140","author":"European Centre for Disease Prevention and Control"},{"key":"10.1016\/j.vaccine.2026.128790_bb0145","series-title":"Protocol for pneumococcal disease [internet]","author":"Junta de Andaluc\u00eda","year":"2017"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128790_bb0150","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2025.2521845","article-title":"The rise of serotype 8 is associated with lineages and mutations in the capsular operon with different potential to produce invasive pneumococcal disease","volume":"14","author":"P\u00e9rez-Garc\u00eda","year":"2025","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.vaccine.2026.128790_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2025.108216","article-title":"Rapid increase in serotype 4 invasive pneumococcal disease among vulnerable young male adults in Belgium (2020-2024)","volume":"163","author":"Cuypers","year":"2026","journal-title":"Int J Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128790_bb0160","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms11071816","article-title":"Systematic literature review of the epidemiological characteristics of pneumococcal disease caused by the additional serotypes covered by the 20-valent pneumococcal conjugate vaccine","volume":"11","author":"M\u00e9roc","year":"2023","journal-title":"Microorganisms"},{"issue":"41","key":"10.1016\/j.vaccine.2026.128790_bb0165","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2025.30.41.2500758","article-title":"Third Streptococcus pneumoniae disease outbreak involving serotype 4-ST801 in a shipyard, Finland, May to June 2025","volume":"30","author":"Manca","year":"2025","journal-title":"Euro Surveill"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128790_bb0170","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1093\/infdis\/jiaa501","article-title":"Upsurge of conjugate vaccine serotype 4 invasive pneumococcal disease clusters among adults experiencing homelessness in California, Colorado, and New Mexico","volume":"223","author":"Beall","year":"2021","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128790_bb0175","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S1473-3099(23)00706-5","article-title":"Invasive pneumococcal disease 3 years after introduction of a reduced 1+1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study","volume":"24","author":"Bertran","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128790_bb0180","article-title":"Outburst of serotype 4 IPD after COVID-19 is driven by ST15063\/GPSC162 lineage associated with high-risk behaviors and greater virulence linked to influenza H3N2 virus coinfection and cigarette smoke","author":"P\u00e9rez-Garc\u00eda","year":"2026","journal-title":"medRxiv"},{"issue":"36","key":"10.1016\/j.vaccine.2026.128790_bb0185","doi-asserted-by":"crossref","first-page":"793","DOI":"10.15585\/mmwr.mm7336a3","article-title":"Use of 21-valent pneumococcal conjugate vaccine among U.S. adults: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2024","volume":"73","author":"Kobayashi","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"10.1016\/j.vaccine.2026.128790_bb0190","article-title":"Public health effects of adult pneumococcal vaccination choice amid increased serotype 4 rates in US subpopulations","volume":"249","author":"Smith","year":"2025","journal-title":"Public Health (Lond)"},{"key":"10.1016\/j.vaccine.2026.128790_bb0195","author":"Belgium Superior Health Council"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128790_bb0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.mm7401a1","article-title":"Expanded recommendations for use of pneumococcal conjugate vaccines among adults aged \u226550 years: recommendations of the Advisory Committee on Immunization Practices - United States, 2024","volume":"74","author":"Kobayashi","year":"2025","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128790_bb0205","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1093\/jac\/dkaf085","volume":"80","author":"Schellenberg","year":"2025","journal-title":"J Antimicrob Chemother"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26005992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26005992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:45:02Z","timestamp":1789505102000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26005992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":41,"alternative-id":["S0264410X26005992"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128790","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Young adults at risk of emerging serotype 4 invasive pneumococcal disease vs. other serotypes in Andalusia (Spain), 2022 to 2024: optimising conjugated vaccines strategies","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128790","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128790"}}